Glypican-3 (GPC3)
Glypican-3 (GPC3) is a heparan sulfate proteoglycan tethered to the outer face of the plasma membrane by a glycosylphosphatidylinositol anchor.
Glypican-3 (GPC3) is a heparan sulfate proteoglycan tethered to the outer face of the plasma membrane by a glycosylphosphatidylinositol anchor. In development it modulates growth factor signaling at the cell surface — notably Wnt, Hedgehog and fibroblast growth factor pathways — and its loss-of-function causes Simpson-Golabi-Behmel syndrome, an X-linked overgrowth disorder, while its effects on growth-factor signaling depend on context. Its expression is oncofetal: abundant in fetal liver, silenced after birth, and re-expressed in tumors, where the same protein appears to switch to potentiating Wnt/β-catenin signaling.
That pattern is what makes it useful in hepatocellular carcinoma (HCC). GPC3 is expressed in most hepatocellular carcinomas and is absent from normal liver and from benign lesions such as regenerative nodules, so its detection by immunohistochemistry helps distinguish well-differentiated HCC from cirrhotic nodules and hepatocellular adenoma — a distinction that histology alone can leave unresolved. As a serum marker it complements rather than replaces α-fetoprotein: performance varies between studies and neither is specific to HCC on its own, while combining the two improves detection over either alone. Expression is not confined to liver tumors, appearing in melanoma, squamous lung carcinoma and germ cell tumors, so specificity holds against normal liver rather than against cancer in general.
Being a cell-surface antigen largely absent from healthy adult tissue, GPC3 is also a target rather than only a marker. chimeric antigen receptor T cells, bispecific antibodies, antibody-drug conjugates and peptide vaccines directed at it are in clinical development for HCC, alongside radiolabeled and fluorescent binders for imaging and intraoperative guidance — the same restricted expression serving diagnosis and therapy for the same reason.
Where the papers sit
11 papers from the last 6 months study Glypican-3 (GPC3) directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 human data · 9 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
GPC3 Theranostics in Liver Cancer
GPC3-directed treatment and imaging are moving toward more engineered, localized and paired approaches in hepatocellular carcinoma. Fourth-generation CAR-T cells and cytokine optimization target low-antigen-density tumors, while thermosensitive hydrogels improve local delivery. Albumin-binding peptides and paired radiotheranostics extend GPC3 from a therapeutic target to a platform for PET imaging and treatment monitoring. Biodistribution and antitumor efficacy remain central endpoints.
5 papers · 45.5%
-
GPC3-Targeted Cellular Therapy
GPC3-directed CAR-T and CAR-NK therapies are being engineered to improve efficacy against hepatocellular carcinoma and other solid tumors. Manufacturing changes, electrostatic surface optimization and local delivery seek to improve cell persistence and tumor access. Enoblituzumab combinations and CAR-T cells secreting anti-EpCAM bispecific engagers address antigen heterogeneity. Dual GPC3–VEGFR degradation offers a complementary strategy beyond cellular therapy.
4 papers · 36.4%
-
Others — Liver Cancer Vaccines and Detection
mRNA-loaded lipid nanoparticles are being used to develop neoantigen vaccines for hepatocellular carcinoma, with tumor eradication shown in mice. Alpha-fetoprotein and the tumor microenvironment recur in the cancer-immunology context. A separate nanoplasmonic biosensor work focuses on whole-blood operation rather than vaccination. The cluster therefore links liver-cancer-oriented translational applications without a single clear research direction.
2 papers · 18.2%
GPC3 is used as a directly transduced analyte in an instrument-free whole-blood nanoplasmonic biosensor
The SiNP-chitosan nanocomposite biosensor for hepatocellular carcinoma uses anti-GPC3-functionalized gold nanoparticles embedded in hydrogel beads to convert GPC3 binding in unprocessed finger-prick blood into simultaneous colorimetric and LSPR signals, rather than treating GPC3 only as a tumor-localizing imaging target, vaccine antigen, or therapeutic target. This assigns GPC3 a distinct role as the directly measured analyte in an autonomous point-of-care diagnostic platform, enabling plasma separation and quantitative detection without laboratory instruments or sample processing 42233753Jun.
Papers
The 11 papers from the last 6 months that study Glypican-3 (GPC3) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
GPC3 Theranostics in Liver Cancer (5)
- Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714869
- Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 6 Jul 2026 PMID 42407326
- Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density. Journal of hematology & oncology · 2 Jul 2026 PMID 42387611
- Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42258609
- Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
GPC3-Targeted Cellular Therapy (4)
- Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777829
- Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies. Hepatology communications · 1 Aug 2026 PMID 42538870
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
Others — Liver Cancer Vaccines and Detection (2)
- A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546
- A SiNP-Chitosan Nanocomposite Converts Hydrophobic 3D-Printed Microchannels into Whole-Blood-Operable Nanoplasmonic Biosensors. ACS biomaterials science & engineering · 3 Jun 2026 PMID 42233753
By study type
Human data, design not indexed (1)
- Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 6 Jul 2026 PMID 42407326
Preclinical: animal, cell and lab studies (9)
- Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777829
- Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714869
- Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies. Hepatology communications · 1 Aug 2026 PMID 42538870
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density. Journal of hematology & oncology · 2 Jul 2026 PMID 42387611
- GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
- Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42258609
- Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
- A SiNP-Chitosan Nanocomposite Converts Hydrophobic 3D-Printed Microchannels into Whole-Blood-Operable Nanoplasmonic Biosensors. ACS biomaterials science & engineering · 3 Jun 2026 PMID 42233753
Unclassified: not yet indexed with MeSH (1)
- A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-14. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.